Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 33.3%High 2 · 66.7%

Overall survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

ALK inhibitor leads to lower overall survival compared with any cytotoxic chemotherapy (high certainty).

1 finding from 1 review

Overall survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

Next‐generation ALK inhibitor probably leads to lower overall survival compared with crizotinib (moderate certainty).

1 finding from 1 review

Progression‐free survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

Next‐generation ALK inhibitor leads to lower progression‐free survival: overall population compared with crizotinib (high certainty).

1 finding from 1 review